OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-06-30-accounts

British Society for imrriuriolog Annual Report 2023

Trustees’ Report

For the year ended 30 June 2023

What we do and why it matters

The British Society for Immunology is the UK membership organisation working with scientists and clinicians to forward immunology research and application around the world. Our ambitious and collaborative community consists of over 4,300 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society’s ability to prevent and treat disease.

Our mission

The British Society for Immunology’s mission is to support our immunology community in driving scientific discovery and making a positive impact on health.

We accomplish this by:

The Trustees confirm they have referred to the Charity Commission’s guidance on public benefit when reviewing the Society’s aims and objectives, planning future activities and setting the annual operating plan.

2

Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK’s leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.

3

Connected community

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2023, we had over 4,300 members who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

In December 2022, over 1,700 immunologists came together in Liverpool and online for our flagship event, BSI Congress 2022. It was an amazing four days of immunology, packed with cutting-edge science, inspiring debates and those all-important opportunities to connect and start new collaborations.

We look forward to welcoming the immunology community to Belfast in December for the 2023 BSI Congress.

4

Regional and Affinity Groups

The BSI’s Regional and Affinity Groups are a key part of the BSI community and are part of our core activity to bring our membership together. The scientific discussions and networking that take place via these Groups are invaluable for the continued development of immunology. Our 17 Regional Groups bring together immunologists within a local community, boosting local research networks. Our 14 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our Groups ran a full programme of activities this year with a huge amount of enthusiasm, dedication and expertise. In total, our Groups hosted 12 in-person conferences and two online events, covering a whole host of topics from the ageing immune system to comparative immunology to inflammation at barrier sites. Collectively, these events attracted over 1,500 delegates and played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

BSI Journals

The BSI’s original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been a year of consolidation and growth for our highly respected family of three journals, Clinical & Experimental Immunology, Immunotherapy Advances and Discovery Immunology.

Working with our publishing partner, Oxford University Press, our journals aim to serve the field of immunology through publishing high-quality research articles, reviews, commentaries and short reports from researchers around the globe. We work closely with our Editors-in-Chief and Editorial Boards to take a strategic approach to ensure the continued high-performance of the journals. With our mixed portfolio of both hybrid and fully Open Access journals, the Society is in a strong position to continue to provide for the immunology community’s publishing needs for many years to come.

Income generated from our journals provides major financial support for the Society’s activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.

Our established high quality and translational research journal, Clinical & Experimental Immunology (CEI), continues to go from strength to strength, with a robust impact factor of 4.6 This has been a busy year for the journal, led by Editor-in-Chief Leonie Taams, with several high-profile review series to take a deep dive into key topics including human B cells, inborn errors of immunity and therapeutic options for regulatory T cell enhancing approaches. Additionally, CEI’s collaboration with the Federation of Clinical Immunology Societies (FOCIS) continues to strengthen with the publication of our series on unconventional T cells in health and disease.

5

----- Start of picture text -----
Impact factor
Submissions
4.6 546
(2022: 5.732) (2022: 537)
----- End of picture text -----

----- Start of picture text -----
9.57
Avg citations
per article
(2022: 10.95)
----- End of picture text -----

*Citations are based on articles for previous two years.

Our first fully Open Access journal, Immunotherapy Advances , continues its progress to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, Immunotherapy Advances focuses on scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.

This year, the journal has passed the milestones of being accepted for inclusion in both PubMed Central and Scopus, which is a positive step forward as it means that the journal’s content is more discoverable and searchable. The journal has also kept its foot on the pedal, publishing several special collections covering topics including immune-related adverse events, adoptive cellular therapies and T cell targeted approaches.

It’s been a busy year for Discovery Immunology as we officially launched the content in October 2022 with six research and review articles. This new fully Open Access journal, led by Editor-in-Chief Simon Milling, has a broad scope that focuses on new discoveries in cellular and molecular immunology. Over the course of the year, Discovery Immunology has reached several important milestones, including achieving indexing with the Directory of Open Access Journals (DOAJ). We also launched the journal’s first special collection, focused on checkpoint blockade.

Our focus for the next year is to continue building the reach and impact of the journal through publishing high-quality articles describing novel mechanisms of the immune response.

6

Supporting research consortia

Under our updated strategy, a new area of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a ‘team science’ approach, we aim to use our skills to support cross-sector collaboration efforts to drive forward immunology research faster and more effectively. We have built on our initial success this year by providing a variety of services to support five national research consortia – National Core Studies Immunity, UK Coronavirus Immunology Consortium, CARINA (Catalyst Reducing ImmuNe Ageing) Network, SIREN (SARS-CoV-2 Immunity and Reinfection EvaluatioN) study and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing).

The National Core Studies (NCS) programme was established by the Government Office for Science in summer 2020 to ensure critical questions around COVID-19 could be answered quickly and effectively. The Immunity programme, led by Professor Paul Moss and funded by UK Research and Innovation (UKRI), funded studies that increase our understanding of immunity against COVID-19 and the role that vaccines play in this.

Building on our successful support through the previous 12 months, the BSI continued to run the UK COVID Vaccine Research Hub (www.covidvaccineresearch.org), a highly successful website set up for the public, policymakers and researchers to provide the latest information on COVID-19 vaccine research in the UK. We also ran the Patient and Public Involvement Panel for the consortia, which as well as ensuring the expertise and viewpoints of the public contributors were fed into the research agenda, also included developing a training programme for NCSi researchers and sharing best practice on how to successfully embed PPI in immunology research. Finally, we also supported NCSi researchers in communicating their work to policymakers, the media and the public in an accessible manner to maximise its impact and reach.

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a project funded by the Medical Research Council and Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network aims to establish a UK-wide inclusive platform to enhance collaboration and foster knowledge exchange around immune ageing as well as increasing the profile of the research area.

7

This has been a year of growth for the CARINA network, which now has over 90 members and has delivered a number of initiatives to build the network’s capacity and output. We have run several in person and virtual all full network meetings, with a particular focus on facilitating cross-sector collaborations and gaining a shared consensus of the key research questions within immune ageing. CARINA’s Early Career Forum is at the heart of their activity and have met regularly for spotlight and talks and development discussions. In addition, ECRs have been able to access free training in bioinformatics. CARINA has also successfully brought network members together to formulate innovate collaborative grant proposals focusing on developing biomarkers for immune frailty.

Keeping members informed

The BSI works hard to ensure good communication channels with our members, the wider immunology community and the public informed about our activities and about developments in immunology in the wider world. The popularity of our website continues with 2.11 million page views this year and 1.10 million unique users.

2.11m page views

1.10m unique users

BiteSized Immunology , our online resource designed to form a comprehensive guide to the immune system continues to be popular with six of the top ten most read pages. The BiteSized Immunology: Experimental Techniques: Enzyme-linked immunosorbent assay (ELISA) beat the BSI homepage to become the most visited website page of the year attracting 106,422 page views.

Our social media channels continue to grow in importance as a way of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology. Across all channels, our social media posts were seen over 5.5 million times.

Championing careers

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we have been able to provide to members over the last 12 months.

313 £230k grants members awarded supported

8

Projects supported through our Equality, Diversity and Inclusion Activity Grant include:

Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year has seen our Career Enhancing Grants go from strength to strength to support even more BSI members to reach their career goals. The scheme provides flexible financial support of up to £5,000 to allow individuals to build their skill set and advance their professional development.

£121k
Grants
funded		 34 members
supported
Generate pilot data
Training courses
Lab visits

Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologist with career development and progression. The popularity of this scheme has flourished in recent years with a steady stream of applicants both mentors and mentees and many stories of successful career progression from past participants.

Clinical immunology training days

We partner with the Association of Clinical Pathologists (ACP) to run clinical immunology training days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immunemediated disease. This year saw a return to in person training events around the country, complimented with additional online sessions to cover the broad spectrum of the curriculum. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

9

Training

This year, as part of our strategy to increase our careers offering, we launched a new training function to provide tailored and innovative training to meet the needs of both immunologists, helping them keep their skills up to date and relevant, and non-immunologists, who want to understand the basics of the discipline to help in their jobs. This year, we launched two training offerings in bioinformatics and PPI training; however, we have lots of plans in the pipeline for additional courses – watch this space for more information!

Bioinformatics

This year, we launched a new training programme in bioinformatics, which has been developed and is delivered by Glasgow Bioinformatic Core. It aims to equip wet-lab immunologists, biologists and other life scientists with the skills and confidence to perform their own bioinformatic data analysis. Bioinformatics is now a potent driver of scientific development and an area where there is currently a significant skills gap within immunology. We offer a range of courses, suitable for complete beginners through to advanced practitioners. Through these highly rated courses, our aim is to provide affordable access and high-quality training in this essential skill to the current and future generations of immunologists.

95 people Lecture delivery
Session content
trained 9.63/10 9.63/10

Training in Patient & Public Involvement

As part of our work on National Core Studies Immunity, we teamed up with five of our public contributors from that project to co-design an online course for researchers on how to involve the public and patients in their research, and how to better understand the mindset and approach needed for effective and inclusive involvement. During the course, researchers were able to hear directly from PPI representatives as well as allowing for peer-to-peer learning through sharing experiences and case studies of successful involvement.

Confidence in building rapport and relationships with public contributors increased from 48% before the course to 92% afterwards. Similarly, confidence in giving value to patient and public contributors increased from 9% before the course to 93% after the training.

Honorary members

Our honorary membership scheme recognises individuals who have made an outstanding contribution to immunology and/or to the Society. At BSI Congress 2022, we were delighted to award Lifetime Honorary Membership to two members:

10

BSI Immunology Awards 2023

In April 2023, we revealed the winners of our inaugural BSI Immunology Awards. These awards were created to champion the remarkable achievements of individuals and teams working across the spectrum of immunology to drive excellence in our discipline.

We celebrated the awards at our ‘Transforming the immunology landscape’ event, which was an opportunity for the immunology community to come together to hear about the extraordinary work being undertaken by their peers and discuss future challenges and opportunities across the sector.

Catalysing change

Public engagement

Our public engagement work over the last 12 months has focused primarily on vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around vaccination.

Resources for engagement

We have continued to develop a range of engagement resources around vaccines, including updating our highly rated comprehensive ‘Guide to COVID-19 vaccinations’ and creating an infographic to explain the importance of booster COVID-19 vaccines.

11

We also significantly updated our ‘Guide to childhood vaccinations’ which explains how vaccines work and provides latest information on the UK immunisation schedule, along with developing a new infographic about the polio vaccination campaign in London to encouraged parents to catch up on their child’s vaccines.

We launched a new ‘Guide to vaccinations for adults over 65’ to inform adults aged 65 and over about the different vaccines they are eligible for in the UK and answer common questions. This guide was developed in partnership with the CARINA Network and is sponsored by the UK SPINE Knowledge Exchange Network.

We’ve been working with the EFIS Vaccine Task Force members to translate some of our infographics about how vaccines work into different languages, including Turkish, to make information accessible to diverse communities across Europe.

Additionally, our cancer immunotherapy darts activity featured in the 2023 British Science Week activity packs that were shared with primary schools and community groups across the country.

#VaccineConversations

Empowering our members to engage with their family, friends and communities to have meaningful conversations about vaccines has continued to be a core part of our public engagement work. We held our annual online vaccine engagement day and encouraged members to use their expert voices for a day of education and celebration to champion the critical role of vaccines. These conversations from trusted individuals are incredibly important in strengthening public understanding and helping people make informed decisions about vaccination.

This year, we were excited to return to events in person on a more regular basis, using our interactive activities and resources to engage with all ages about the different components of the immune system, the importance of vaccination and herd immunity. We participated in the Cambridge Big Biology to engage with school-aged children and families, the Science Museum ‘Lates’ aimed at adults over 18 and the Lambeth Country Show to reach communities in London who wouldn’t normally engage with immunology.

12

Supporting our members’ public engagement activities

Our public engagement grant scheme had a revamp this year and was renamed the Communication & Engagement grant, offering our members financial support to develop and deliver their own public engagement activities. We funded twelve successful applications, including a public engagement stall at Glastonbury festival around the immune system and gut microbiome, showcasing the importance of immunology in health and disease. The stall interacted with an estimated 1,200 people over the weekend and overall, feedback was very positive with visitors expressing their interest in immunology and microbiome research.

Partnership for maximum impact

To build public trust and confidence in vaccines, it’s important that we work with a variety of organisations to increase our reach into different communities. We partnered with the London Borough of Bexley to create short videos featuring BSI members answering common questions about different aspects of childhood vaccinations, which are played in GP surgeries, shared across community groups and featured online. We also supported NHS England with their social media ‘fact cards’ answering common questions about COVID-19 vaccine boosters targeted for Black African, Black African Caribbean and Asian communities. These were also used to engage local and national community groups, for example shared by the British Islamic Medical Association (BIMA) and mosques in their WhatsApp groups. We also collaborated with NHS England to develop a new animation about routine vaccinations aimed at families. The animation is shared widely on YouTube and social media. Furthermore, we joined IUIS to celebrate International Day of Immunology for which our president featured in a short public-facing video around the theme of "Immunology talks to public health".

We recognise the importance of sharing best practice of public engagement around vaccines and were invited to present at the UK Health Security Agency conference in late October. This key event brought together experts from local government and public health and was an excellent opportunity to showcase the impact our work has had to a large audience.

Training community champions to have effective vaccine conversations

There has never been a more important time for immunologists to engage with the public about vaccinations by listening to and addressing questions and concerns. We expanded our public engagement work around training community champions to have effective conversations about vaccinations. This year, we collaborated with Birmingham City Council on a programme to train ‘vaccine champions’ within local community groups to have effective conversations with their peers about vaccinations, including COVID-19, childhood, HPV and flu vaccines.

The training was co-designed with the local authorities’ public health teams and their residents, addressing specific questions and key concerns raised by participants and their communities. The programme consisted of accessible online sessions for one hour each week over four weeks. The sessions were led by BSI members who have specialist knowledge of vaccines and honed skills in engagement and communication.

The sessions focus on building understanding of how vaccines train the immune system, as well as developing skills in listening to and answering common questions and sometimes complex worries. Sessions are also supported by our public-friendly resources about vaccines that participants can use and signpost people to.

13

After completing the training, 100% of community champions in Birmingham strongly agreed or agreed that they felt informed and knowledgeable about vaccines as well as confident to have effective conversations about vaccines. Encouragingly, all community champions reported an increase in the number of people they regularly talk to about vaccinations.

Patient and public involvement

Following our delivery of patient and public involvement (PPI) within the UK Coronavirus Immunology Consortium (UK-CIC), we published our experiences as a paper in the journal Research Engagement & Involvement detailing the positive impact of PPI in the UK-CIC. The paper was coauthored with public contributors who worked with us in the PPI panel within UK-CIC and shared our experiences of running the project and lessons learnt. UK-CIC brought together laboratory-based scientists and clinicians with the experience and unique perspectives of patient and public contributors. The PPI panel within UK-CIC provided a platform for regular two-way conversations with researchers to address key questions about the implications of the research as well as discussions about what was important to the public and patient groups.

This year, we continued to support the National Core Studies Immunity programme and led on the PPI element of the project. We hosted a free public webinar about the research being undertaken to study the immune response to COVID-19 boosters, which included opportunity for the public to submit questions they had around COVID-19 vaccines.

We were proud to launch a new report in association with National Core Studies Immunity entitled 'Patient and public involvement in COVID-19 research: bridging the gap between theory and practice'. The report explored the impact of PPI in COVID-19 research with the aim of encouraging more research teams to consider involving patients and the public in their work, and to provide practical examples of how this can be done to great effect. It was produced with substantial contribution from a group of patients, carers and members of the public and described how research teams working as part of National Core Studies Immunity involved patients and the public in their work, as well as what it means to involve public contributors in research more generally.

14

Policy highlights

This year, the Society has continued to use our powerful voice to advocate for immunological science and health, ensuring the voice of immunologists is heard loud and clear in public debates and that policymakers have access to the latest immunological thinking. With our dynamic approach, working in partnership with BSI members and with our COVID-19 Taskforce, we have played a strong role in both ensuring the expert voice of immunologists is represented in public debate and how the lessons learnt from the COVID-19 pandemic response can be brought to wider areas of health research.

Engaging with stakeholders

Through our policy and public affairs work, we aim to engage with policymakers and stakeholders to ensure the viewpoint and interests of immunologists are represented in public debate. Over the past year, we have:

15

Enablers

To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:

Enabler - membership

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology continues to grow and evolve, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our community. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

To continue supporting our diverse and ever-growing community, we revamped our membership categories in July 2022. Five categories grouping some of the most common areas in which our members work were introduced. We will continue to provide tailored benefits for each career stage of each category.

Our new membership categories showcase the different sectors that encompass our vibrant community. We also expanded the criteria for the Early Career Membership to include anyone in the first seven years from receipt of their PhD. A new category for those retired from full-time employment was also introduced. The BSI continues to offer concessionary discounts and free membership to various groups.

16

Providing the best service for our members

One of our key aims is to ensure that increase our support and engagement with our members from all sectors and at all career stages. To support this work, this year we carried out a major project to embed a new membership management system to allow us to provide better, more joined up and holistic support and service for our members. Alongside this, we also upgraded our website to increase functionality and accessibility as well as making it easier to navigate. Both projects have now been successfully implemented resulting in a seamless experience for our members to better interaction with our services.

BSI Clinical Immunology Professional Network

Following the successful merger between the British Society for Immunology (BSI) and the UK Primary Immunodeficiency Network (UKPIN) in early 2023, we have established the BSI Clinical Immunology Professional Network (BSI-CIPN) – a new network championing clinical immunology within the BSI.

17

In combining the expertise of the BSI and UKPIN, the network aims to foster closer links between clinical practitioners and basic scientists and strengthen the voice of clinical immunology in policy and public arenas. The BSI-CIPN will also share best practice through a range of resources and activities, including dedicated events, clinical sessions at BSI Congress, development of clinical guidelines, training provision and much more. By providing this strong platform for UK clinical immunology, our aim is to improve care for patients.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including clinicians and trainees, nurses, healthcare scientists and pharmacists.

Having spent this year embedding the network within wider BSI activities, we now have an eye on the future and an exciting programme of activities planned for the next 12 months. Watch this space for more details.

Immunology Nursing Competency Framework

In May, we were delighted to publish the first ever competency framework for immunology nursing in the UK to advance patient care and nursing practice. Immunology nursing plays a vital role in the healthcare system, providing essential support to individuals with complex and diverse immunerelated conditions, and demanding a highly skilled and competent nursing workforce. By combining underlying immunology knowledge with clinical best practices and the latest therapeutic advances, this framework provides a comprehensive roadmap for mastering the skills and knowledge required in immunology nursing, covering all career grades from newly entering into the speciality to undertaking nurse-led clinics. Our aim is for this framework to be flexible and to empower immunology nurses to stay abreast of advancements while working innovatively to improve standards of care for patients.

BSI-CIPN meeting

To celebrate the launch of the BSI-CIPN, we held a one-day conference in tandem with the BSI Congress to bring together the clinical immunology community on the topic of ‘Expanding horizons within clinical immunology: Redefining the scope of clinical practice’. The successful event brought together over 100 professionals working in clinical immunology to discuss diverse topics such as COVID-19 and primary immunodeficiencies, the new UK perioperative anaphylaxis network as well as learning more about the aims and ambitions of the BSI-CIPN.

18

Immunology News

Members in the UK can receive a printed copy of our quarterly membership magazine, Immunology News , with online access around the world. Immunology News amplifies the voice of our membership and highlights how we’re supporting our members and representing immunology on a wider stage.

Over the last year editions featured new BSI membership categories, women in immunology, the BSI’s new Bioinformatics training courses, BSI and UKPIN merger and the creation of the BSI-CIPN, training community vaccine champions, an international BSI’s member’s perspective, the 2022 BSI Summer School and the launch of our new journal Discovery Immunology.

There were also interviews with the outgoing and new Presidents, Prof Arnie Akbar and Prof Tracy Hussell.

This year also included a recap of highlights from BSI Congress 2022 and highlights from the celebration of the immunology community at the inaugural BSI Immunology Awards.

19

Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work

20

Enabler - Equality, diversity and inclusion

The BSI wants diversity and inclusion to be at the heart of the ethos of our community. This year, we have continued to build on the promises laid out in our ‘Diversity and Inclusion Framework’, which outlines our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members’ needs. By building on past and ongoing activities, this framework set out our long-term plan of action for diversity and inclusion at the BSI.

This year, we have made significant steps forward in our EDI commitment, carrying out an organisational wide review of how EDI is embedded within our activities and how are staff are supported in delivering these and developing their knowledge of best practice in EDI. We have also engaged much more deeply with our wider membership around understanding their views of the BSI’s role in supporting EDI within immunology, what we are doing well and what we could do better. In September, we held two focus groups with a wide cross section of our membership and received some incredibly useful feedback as well as ideas and suggestions for future activities that we are taking forward. Watch this space! We also ran a session at BSI Congress on EDI, highlighting some successful case studies from our Equality, Diversity and Inclusion Activity Grant scheme as well as getting members’ feedback on the implementation of our Diversity and Inclusion Framework.

Finally, we have been engaging deeply with the wider scientific community to spread best practice on how we developed our framework and to learn from their experiences of similar activities.

Enabler - Financial sustainability

Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. While traditionally we have relied heavily on our journal income to fund charitable activities, our shift to bring in new long-term and stable income sources is now well under way. The development of new income streams is never a quick process as there is often a delay between investment and return, requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose – to support the organisation through this transition – and their use is now carefully planned

Consolidating our approach

Last year, we reported on changes to our journals with the aim of moving our financial reliance away from traditional subscription journals to develop a modern publishing portfolio that also meets the needs of our members and wider immunology community. This work is now well underway, and this year saw the growth of our two new Open Access journals, Immunotherapy Advances and Discovery Immunology, which are proving popular additions to the BSI portfolio. Both journals have met key milestones this year on their journey towards gaining an impact factor and stabilising our future journals income.

21

Our new activity to provide support to wider immunology research efforts is also paying dividends and we have built up a strong reputation within the sector for assisting the smooth running, effectiveness and impact of large research consortia. Prestigious projects we have worked on over the last 12 months include UK Coronavirus Immunology Consortium, SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, National Core Studies Immunity, the CARINA (CAtalyst Reducing ImmuNe Ageing) Network and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID19 Risk Using Antibody Testing). Our participation in this type of funded project continues to be an important source of income while allowing us to meet our wider goal of supporting the national immunology research effort.

New endeavours

This year has seen the launch of several new projects, which fulfil our goals of making a positive contribution to the immunology sector while also diversifying the BSI’s income. Chief among these has been the launch of a BSI training function to support immunologists and the wider research community to keep their skills up to date and relevant. Our first training offering on bioinformatics, delivered in partnership with Glasgow Bioinformatic Core, has proved hugely popular, with exceptionally positive feedback, and provides vital training in a growth area for immunology. We also piloted a training course for researchers in public and patient involvement, which we hope to role out further next year. These courses, along with several new offerings in pipeline which particularly focus on the clinical sector, mean the BSI is well on our way to establishing ourselves as a leading training provider in the immunology sector.

We are also enhancing our partnership and sponsorship areas of work with industry, establishing mutually beneficial routes for collaboration to highlight, celebrate and champion the immunology sector, which has been core to our strategic development of this area of work. Notably among these is the launch of our new Immunology Awards ceremony which brings together leaders from across the immunology sector to celebrate the potential of immunology to make positive contributions to wider society and public health.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society’s registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society’s governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 56.

22

The Trustees are responsible for directing the Society’s activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Member Representative Forum

The Membership Representative Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI’s ‘think tank’ and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI’s flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

BSI-CIPN Steering Group

The BSI-CIPN Steering Group directs the activities of the BSI-CIPN. The group consists of both elected (from the BSI-CIPN members) and co-opted immunology professionals (chosen because of their roles in other key organisations).

23

Group structure

The Society has two wholly owned subsidiaries:

BSI Trading Limited is registered in England and Wales under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition and other trading activities for the Society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) is a registered charity (1164466) and a company registered in England and Wales (09273983). The principal activity is the advancement and support of clinical immunology, especially the health among those with primary immunology deficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society’s Clinical Immunology Professional Network (BSICIPN).

Financial Performance

The BSI continued our transition period following the changes to our publishing portfolio. The annual net deficit reduced by 35% from £0.63m last year to £0.41m this year. The operating deficit before investments were better than budget.

The BSI recorded its highest ever income reaching £2.45m, 11% higher than 2022.

----- Start of picture text -----
Income
2023 £2.45m
2022 £2.21m
----- End of picture text -----

Publishing income remains the BSI’s largest source of income, however it continued to fall from 41% of total BSI income in 2022 to 31% this year. This fall was offset by increases in income from Congress and grants and donations.

----- Start of picture text -----
2023 2022
Journals 31% 41%
Congress 26% 23%
Grants and donations 17% 13%
Membership 7% 7%
----- End of picture text -----

Congress 2022 attracted a record number of delegates and increased income from exhibition space hire and sponsorship.

The Society continued our success obtaining funding for our work supporting immunology research. Total grants received were over £0.2m for the second consecutive year. Total donations of £0.21m were received in 2023. This includes £0.18m from UKPIN following the merger with the BSI during the year.

The newly launched BSI-CIPN held its first meeting in December 2022, this attracted over £100k of sponsorship income. It is anticipated that the BSI-CIPN will assist in creating partnerships with industry leading to exciting projects in future years.

24

In their second year, the BSI funded career enhancing grants of £121k. This continues to be an important source of career support to our members.

Increased sales of exhibition space and sponsorship at Congress helped push BSI Trading Limited to an annual profit of £0.49m (2022: £0.34m). This was gifted to the society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) posted a loss of £5k for the period.

The Society is in a transition period following the reduction in journal income. The Society is focusing on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating significant levels of income.

Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

UK events including the 2022 mini budget, the high level of inflation together with global events such as the Russian invasion of Ukraine created another challenging year for investments.

As planned the BSI commenced our programme of drawdowns from investments as we invest in new sources of sustainable income. During the year £1m was withdrawn from our investments to help meet the BSI’s cash requirements.

Funds are invested with abrdn (formerly Aberdeen Standard Chartered) with a long-term objective to generate a capital return of 3% more than inflation over a three year rolling period. As noted above performance was challenging this year resulting in a small net loss of £0.007m (2022: £0.51m gain). The value of the portfolio fell by £0.94m (2021: fall of £0.31m) because of the drawdowns. On 30 June 2023 investments were valued at £3.30m (2022: £4.26m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund invest in new income sources securing the BSI’s long term financial health.

The risk register is reviewed annually with monetary values allocated to specific risks. This value is added to the total of restricted and designated funds. A provision for unknown risks (to give cover for those risks of which the society is not yet aware) is then added to produce the required reserves level. The calculation of the required reserves level is performed on an annual basis.

The latest review resulted in total required reserves of £3.78m (2022: £3.76m). On 30 June 2023 total reserves were £3.90m, (2022: £4.31m), this was £0.12m more than the total required reserves. The charity held free reserves (unrestricted reserves less fixed assets) of £2.95m (2022: £3.25m). Details of restricted funds can be found in note 15 of the accounts with details of designated funds in note 16.

25

Pay policy

The Society’s pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including the Senior Management Team, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society’s is voluntarily reporting its gender pay gap. Calculated in June 2023 the Society’s mean gender pay gap is 23% (June 2022: 32%). The pay gap indicates that while 75% of employees are women (2022: 72%), most men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and mange risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society’s strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society’s strategic and compliance risks twice a year.

The principal risks and uncertainties facing the society and the mitigations that we have put in place are as follows:

26

Risk: short term Risk response
Development of new
surplus generating training
function		 The Society has performed detailed market analysis and is focussing
development of training in areas where demand has been identified.
The BSI are working with partners to develop and market courses.
Regular review of delegates numbers and experiences are
performed to ensure courses are relevant.
Unable to recruit the right
people		 Upon coming vacant all roles are reviewed to ensure they are
relevant, job descriptions are reviewed and updated to ensure they
are clear. Roles are benchmarked to market rates and we conduct a
transparent and inclusive recruitment process.
Risk: long term Risk response
Inflation – rising costs The Society regularly reviews value for money from our suppliers
and potential impacts on future sustainability, proposing action as
required.
Failure to find new sources
of long term sustainable
income		 The Society is proactively looking for new funding opportunities:
▪ Working with partners and corporate members to develop existing
and new sources of income
▪ Developing a programme of training courses with partners
including University of Glasgow
Loss of significant
devaluation of
investments
A devaluation in the value
of investments would
result in a reduction of
reserves available to use by
the Society.
Investments could be
impacted by sudden
unforeseen global events		 The Society
▪ Reviews investment performance during each Financial Sub
Committee meeting
▪ Communicates regularly with our investment managers, especially
through times of significant volatility

27

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters’ data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

During 2023-24 the Society will focus on:

Connected community

Championing careers

Catalysing change

Enabler - membership

Enabler - Equality, diversity and inclusion

Enabler - Financial sustainability

The Senior Management Team and the Trustees continue to assess all significant risks, in the immediate, medium and longer term.

Trustees’ responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees’ report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

28

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:

Tracy Hussell BSI President

Date: 18 October 2023

29

Independent Auditor’s Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2023 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group’s and the parent charitable company’s affairs as at 30 June 2023 and of the group’s incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

30

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees’ annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and

the trustees’ annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or

the parent charitable company’s financial statements are not in agreement with the accounting records and returns; or

certain disclosures of trustees’ remuneration specified by law are not made; or

we have not received all the information and explanations we require for our audit; or

the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees’ Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

31

Auditor’s responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of noncompliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

32

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company’s internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity’s trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters which we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company’s members, as a body, and the charity’s trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Neil Finlayson (Senior Statutory Auditor) for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Date 7 December 2023 9 Appold Street London EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

33

British Society for Immunology

Consolidated Statement of Financial Activities Year to 30 June 2023

Note
Income from:
Grants and donations
2
Investments
3
Charitable activities
4
Membership
BSI-CIPN
Partnership work
Congress
Meetings and events
Journals
Training		 General
Designated
Restricted
Total
Total
funds
funds
funds
2023
2022
£'000
£'000
£'000
£'000
£'000
-
-
425
425
280
132
-
-
132
151
162
-
-
162
160
105
105
-
105
-
15
120
136
643
-
-
643
512
83
-
-
83
59
749
-
-
749
913
28
-
-
28
-
Unrestricted funds
Total income
Expenditure on:
Raising funds
Investment management fees
Cost of raising funds
Charitable activities
Membership
BSI-CIPN
Partnership work
Congress
Meetings and events
Journals
Training
Education and Careers
Diversity and inclusion
National Research support
Policy and Public Affairs
Public engagement
Communications
International work		 2,007
-
440
2,447
2,211
35
-
-
35
41
12
-
-
12
30
241
-
-
241
240
80
-
-
80
-
147
-
-
147
133
720
-
-
720
642
289
-
-
289
184
370
-
-
370
370
35
59
-
94
-
64
136
-
200
198
2
-
-
2
4
-
-
129
129
149
21
-
158
179
175
72
-
38
111
118
221
-
-
221
228
23
-
-
23
28
Total expenditure
5
Net income (expenditure)
before gains (losses) on
investments and transfers
Net gains/(losses) on
investments
12
Transfers between funds		 2,333
195
325
2,853
2,540
(326)
(195)
115
(406)
(330)
(7)
-
-
(7)
(305)
23
(23)
-
-
Net income/(deficit)
Reconciliation of funds:
Funds brought forward		 (310)
(218)
115
(413)
(635)
3,396
771
143
4,310
4,944
Funds carried forward 3,086
553
258
3,897
4,310

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 37 to 55 form part of these financial statements

34

British Society for Immunology Balance Sheet 30 June 2023

Fixed assets
Tangible fixed assets
10
Intangible assets
11
Investments
12		 2023
2022
2023
2022
53
49
53
49
79
93
79
93
3,299
4,259
3,306
4,259
3,431
4,401
3,438
4,401
692
552
1,225
875
578
407
25
37
1,270
959
1,250
912
(804)
(1,050)
(788)
(1,003)
466
(91)
462
(91)
3,897
4,310
3,900
4,310
3,086
3,396
3,089
3,423
553
771
553
771
3,639
4,167
3,642
4,194
258
143
258
116
3,897
4,310
3,900
4,310
Group
Charity
2023
53
79
3,299
3,431
692
578
1,270
(804)
466
3,897
3,086
553
3,639
258
Current assets
Debtors
13
Cash at bank and in hand
Liabilities:
Creditors: amounts falling due
within one year
14
Net current assets
Net assets
Funds:
Unrestricted funds
General fund
Designated fund
16
Restricted funds
15
Total 3,897

As permitted by s408 Companies Act 2006, the company has not presented its own income and expenditure statement and related notes. The company's loss for the year was £409,171 (21/22 FY: £631,850.

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 18 October 2023 and were signed on its behalf by:

Tracy Hussell , President

British Society for Immunology, Company Limited by Guarantee

Company Registration Number 03005933 (England and Wales)

The notes on pages 37 to 55 form part of these financial statements

35

British Society for Immunology

Consolidated Statement of Cash Flows

30 June 2023

2023 2022
£'000 £'000
Cash flows from operating activities:
Net cash provided by operating activities (893) (765)
Cash flows from investing activities:
Income from investments 132 151
Purchase of tangible fixed assets (21) (40)
Purchase of intangible fixed assets - (57)
Proceeds from the disposal of investments 1,669 521
Purchase of investments (933) (659)
Net cash used in investing activities 847 (83)
Change in cash and cash equivalents in the year (46) (848)
Cash and cash equivalents at 1 July 2022 637 1,485
Cash and cash equivalents at 30 June 2023 591 637
Net income for the period (as per the statement of financial activities) (413) (635)
Adjustments for:
Depreciation charge 30 9
(Gains) losses on investments 7 305
Investment income (132) (151)
(Increase) decrease in debtors (140) (422)
Increase(decrease)in creditors (245) 129
Net cashprovided by operating activities (893) (765)
Analysis of cash and cash equivalents
Cash at bank and in hand 578 407
Cash held byinvestment managers 13 230
Total cash and cash equivalents 591 637

The notes on pages 37 to 55 form part of these financial statements

36

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102.

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the sue of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the post pandemic impact on the Society and Group. This includes regular review of the impact on our members and resulting changes in focus of our activities to support them. Trustees review regular updates on performance against KPIs, rolling forecasts, the risk register and in depth financial reports.

Following the pandemic, the immunology community is busier than ever, attracting new funding to support it's essential work to improve public health. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

37

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

38

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

39

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

2 Income from grants and donations

2023 2022
Unrestricted Restricted Total Total
funds funds funds funds
£'000 £'000 £'000 £'000
Grants - 217 217 249
Donations - 208 208 31
Total - 425 425 280

3 Income from investments and interest

2023 2022
Unrestricted Restricted Total Total
£'000 £'000 £'000 £'000
Listed investments
Investment Income 131 - 131 151
Bank deposit interest 1 - 1
 -
Total 132 - 132 151

4 Income from charitable activities

Unrestricted Restricted 2023 2022
funds funds Total Total
funds funds
£'000 £'000 £'000 £'000
Member subscriptions 162 - 162 160
BSI-CIPN 105 - 105
 -
Corporates and partnership income 105 15 120 136
Congress 643 - 643 512
Meetings and events 83 - 83 59
Journals 749 - 749 913
Training 28 - 28
 -
Total 1,874 15 1,889 1,780

40

Notes to the financial statements

5 Total expenditure

5 Total expenditure
2023
Unrestricted
funds		 Designated
funds		 Restricted
funds		 Total
£'000 £'000 £'000 £'000
Raising funds
Investment management fees 35 - - 35
Fundraising 12 - - 12
Charitable Expenditure:
Membership 241 - - 241
BSI-CIPN 80 - - 80
Partnership work 147 - - 147
Congress 720 - - 720
Other meetings and events 289 - - 289
Journals 370 - - 370
Training 35 59 - 94
Education and Careers 64 136 - 200
Diversity and inclusion 2 - - 2
National Research support - - 129 129
Policy and Public Affairs 21 - 158 179
Public engagement 73 - 38 111
Communications 221 - 221
International Work 23 - - 23
Total 2,333 195 325 2,853

Allocation of support costs to charitable activities:

Allocation of support costs to charitable activities:
Direct Support 2023
costs costs Total
£'000 £'000 £'000
Raising funds
Investment management fees 35 - 35
Cost of raising funds 12 - 12
Charitable activities
Membership 185 56 241
BSI-CIPN 52 28 80
Partnership work 119 28 147
Congress 664 56 720
Other meetings and events 261 28 289
Journals 290 80 370
Training 66 28 94
Education and Careers 173 27 200
Diversity and inclusion 2 - 2
National Research support 129 - 129
Policy and Public Affairs 135 44 179
Public engagement 83 28 111
Communications 117 104 221
International Work 23 - 23
Total 2,346 507 2,853

41

Notes to the financial statements

5 Total expenditure (continued)

Support costs are as follows:

Support costs are as follows:
2023 2022
£'000 £'000
Staff costs 220 198
Premises costs 38 30
Depreciation 22 9
IT and electronic communications costs 90 67
Other 108 81
Recruitment fees 11 0
Governance costs(note 6) 18 13
Total 507 398

Support costs have been allocated based on time spent by departments supporting the various activities.

activities.
Unrestricted
funds		 Designated
funds		 Restricted
funds		 2022
£'000 £'000 £'000 £'000
Raising funds
Investment management fees 41 - - 41
Fundraising 30 - - 30
Charitable Expenditure:
Membership 240 - - 240
Congress 642 - - 642
Other meetings and events 184 - - 184
Publications and journals 370 - - 370
Policy and public affairs 130 - 45 175
National Research support - - 149 149
Partnership work 133 - 133
Education and careers 68 125 5 198
Diversity and inclusion 4 - - 4
Public engagement 116 - 2 118
Communications 228 - - 228
International work 28 - - 28
Total 2,214 125 201 2,540

42

Notes to the financial statements

6 Governance costs

2023 2022
£'000 £'000
Auditor’s remuneration - audit 14 12
Auditor’s remuneration - other 4 1
Total 18 13

7 Net income before gains (losses) on investments

This is stated after charging: 2023 2022
£'000 £'000
Staff costs (note 9) 1,229 1,182
Depreciation 30 9
Auditor’s remuneration - audit 14 12
Auditor’s remuneration - other 4 1

43

Notes to the financial statements

8 Staff costs

Staff costs during the year were as follows:

Staff costs during the year were as follows:
2023 2022
£'000 £'000
Wages and salaries 1,054 1,009
Social security costs 122 118
Pension costs 53 55
Total 1,229 1,182

The average monthly number of employees during the year was as follows:

2023 2022
Direct charitable activities 15 16
Administration of the charity 3 3
18 19

Number of employees whose annualised emoluments fall within following ranges for the year:

the year:
2023 2022
£60,001 - £70,000 1 1
£80,001 - £90,000 2 2
£140,001 - £150,000 1 1

Pension contributions for these employees were £22,601 (2022 - £21,848).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2022 – 19).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £524,335 (2022 - £516,095).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 67% female 33% male (2022: 74% female 26% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

9 Trustees’ remuneration

No trustees received any remuneration for his or her services during the year (2022 – none). During the year expenses totalling £6,933 (2022 - £4,783) were reimbursed to 14 trustees (2022 – 7). In addition £9,293 was paid for travel and accommodation costs on behalf of trustees (2022: £5,483).

In 2022 one trustee received a £250 BSI Congress 2021 Education and Public poster prize for best presentation and a Communicating Immunology grant of £1,000 for his project entitled 'Superbugs'.

44

Notes to the financial statements

10 Tangible assets of the Group and charity

Website Computer
equipment		 Total
£'000 £'000 £'000
Cost or valuation
At 1 July 2022 38 30 68
Additions 18 3 21
Disposals -
 -
 -
At 30 June 2023 56 33 89
Depreciation
At 1 July 2022 - 20 20
Charge for the year 9 7 16
Eliminated on disposal -
 -
 -
At 30 June 2023 9 27 36
Net book value
At 30 June 2023 47 6 53
At 1 July 2022 38 10 48

11 Intangible assets of the Group and charity

IT software Total
£'000 £'000
Cost or valuation
At 1 July 2022 93 93
Additions -
 -
Disposals -
 -
At 30 June 2023 93 93
Depreciation
At 1 July 2022 -
 -
Charge for the year 14 14
Eliminated on disposal -
 -
At 30 June 2023 14 14
Net book value
At 30 June 2023 79 79
At 1 July 2022 93 93

Construction of a new CRM system was completed during the year.

45

Notes to the financial statements

12 Investments

Market value at 1 July 2022
Disposals proceeds
Realised gains/(losses)
Additions at cost
Unrealised gains
Market value at 30 June 2023
Cash held with investment managers
Investment in UKPIN		 2023
2022
2023
2022
£'000
£'000
£'000
£'000
4,029
4,196
4,029
4,196
(1,669)
(521)
(1,669)
(521)
14
(57)
14
(57)
933
659
933
659
(21)
(248)
(21)
(248)
3,286
4,029
3,286
4,029
13
230
13
230
--
7-
Group
Charity
Total investments 3,299
4,259
3,306
4,259

Total Group investments includes £100 investment in subsidiary.

At 30 June 2023 the listed investments
comprised the following:
UK equities
Overseas equities
Investment instruments		 2023
2022
2023
2022
£'000
£'000
£'000
£'000
816
1,244
816
1,244
1,779
2,270
1,779
2,270
691
515
691
515
Group
Charity
Total 3,286
4,029
3,286
4,029
Historical cost of listed investments 2,805
3,317
2,805
3,317

Investments representing more than 5% of the total market value of the portfolio of listed investments are as follows:

follows:
Market
Cost value
2023 2023 Portfolio
£'000 £'000 %
Aberdeen Standard Capital Offshore Fixed Interest Fund Institutional
Income Z GBP 240 209 6.35%

46

Notes to the financial statements

12 Investments (continued)

Investment in subsidiary undertaking

The Society has two wholly owned trading subsidiaries. A summary of their trading results are shown below.

BSI Trading Limited is incorporated in England and Wales, registered number 01021739. Its registered office is 9 Appold Street London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

The Society become sole member of United Kingdom Primary Immunodeficiency Network (UKPIN) on 20 December 2022 and accordingly on that date UKPIN became a subsidiary of the group. During the year UKPIN transferred £175k to the Society being most of its net assets on the acquisition date.

UKPIN is incorporated in England and Wales, registered number 09273983. Its registered office is 9 Appold Street, London EC2A 2AP. The principal activity of the company was the advancement of health among those with primary immunodeficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Societys' Clinical Immunology Professional Network (BSI-CIPN).

A summary of the results of the subsidiaries is shown below:

Turnover
Operatingcosts		 2023
BSI Trading
UKPIN
Total
Limited
£'000
£'000
£'000
576
-
576
-
-
-
576
-
576
(87)
(5)
(92)
489
(5)
484
(489)
(175)
(664)		 2022
BSI Trading
UKPIN
Total
Limited
£'000
£'000
£'000
354
-
354
-
-
-
Operating profit 354
-
354
Administration costs
Profit(loss) for the financial period
Distribution toparent charity		 (19)
-
(19)
335
-
335
(335)
-
(335)
Retained in subsidiary -
(180)
-		 -
-
-
The assets and liabilities of the subsidiaries were:
Assets
Liabilities		 600
2
602
(600)
-
(600)		 388
-
388
(388)
-
(388)
Net assets -
2
2		 -
-
-

47

Notes to the financial statements

13 Debtors

Trade debtors
Prepayments and accrued income
Amount owed by subsidiary undertaking		 2023
2022
£'000
£'000
389
358
303
194
-
-
692
552
Group		 Charity Charity
2023
£'000
425
303
497
1,225		 2022
£'000
341
194
340
Total 875

14 Creditors

Trade creditors
Other taxes and social security costs
VAT payable
Other creditors
Accruals and deferred income		 2023
2022
£'000
£'000
74
355
40
39
9
5
177
124
504
527
Group		 Charity
2023
2022
£'000
£'000
74
345
40
39
9
5
177
124
488
490
Total 804
1,050		 788
1,003
Included within the above is deferred income as
set out below:		 Group Charity
2023 2023
£'000 £'000
Deferred income brought forward at 1 July 459 422
Additional income deferred during the year 437 422
Brought forward funds released in the year (459) (422)
Deferred income carried forward at 30 June 437 422

Deferred income comprises advance payments of journal royalties and memberships fees.

48

Notes to the financial statements

15 Restricted funds

At 1 July At 30 June
2022 Income Expenditure 2023
Meeting funds 34 - - 34
BSI-CIPN - 178 - 178
Autoimmunity 12 - (12) -
UK-CIC - 63 (63) -
Vaccine taskforce 1 25 (26) -
UK Covid Vaccines Research 61 63 (124) -
Ageing and immunity - 68 (40) 28
SIREN 8 9 (17) -
Immunogenicity project 27 15 (42) -
STRAVINSKY - 15 (1) 14
Visiting Scholar and Jonathan Sherrard Awards - 4 - 4
Total 143 440 (325) 258

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

BSI-CIPN

Funds transferred from UKPIN upon the merger to be used to promote and support clinical immunology through the BSI-CIPN

Autoimmunity

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for administrative support for the development and management of the autoimmune research initiative.

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

49

Notes to the financial statements

15 Restricted funds (Continued)

Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the

SIREN project funded by the UK Health Security Agency.

Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

STRAVINSKY

Funds to support a 2 year study aiming eo establish if antibody testing can identify who remains at greatest

risk of severe COVID-19 infection after vaccinations.

Visiting Schloar and Jonathan Sherrard Awards

Funds to support members for periods of training in academic or clinical centres to further their knowledge of primary immunodeficiences.

At 1 July At 30 June
2021 Income Expenditure 2022
£'000 £'000 £'000 £'000
Meeting funds 34 - - 34
Autoimmunity 10 15 (13) 12
UK-CIC (24) 53 (29) -
Vaccine taskforce - 25 (24) 1
BiteSized immunology 5 - (5) -
UK Covid Vaccines research - 157 (96) 61
Ageing and immunity - 24 (24) -
SIREN 10 (2) 8
Immunogencity project - 35 (8) 27
Total 25 319 (201) 143

16 Designated funds

At 1 July Designated Utilised / At 30 June
2022 in year released 2023
Long term sustainability 248 - (150) 98
Training - 150 (59) 91
CRM project 23 - (23) -
Career development programme 500 - (136) 364
Total 771 150 (368) 553

50

Notes to the financial statements

16 Designated funds (Continued)

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Training

Funding for the creation and development of a new surplus generating training function within the BSI.

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

17 Analysis of nets assets between funds

2023
Unrestricted
funds		 Designated
funds		 Restricted
funds		 Total funds
Group £'000 £'000 £'000 £'000
Tangible fixed assets 53 - - 53
Intangible assets 79 - - 79
Investments 3,299 - - 3,299
Current assets 458 553 258 1,269
Current liabilities (804) - - (804)
Total Funds 3,086 553 258 3,897
2023
Unrestricted
funds		 Designated
funds		 Restricted
funds		 Total funds
Charity £'000 £'000 £'000 £'000
Tangible fixed assets 53 - - 53
Intangible assets 79 - - 79
Investments 3,306 - - 3,306
Current assets 439 553 258 1,250
Current liabilities (788) - - (788)
Total Funds 3,090 553 258 3,901

51

Notes to the financial statements

17 Analysis of nets assets between funds (Continued)

The total unrealised gains (losses) as at 30 June 2023 constitutes movements on revaluation and are as follows:

2023 2022
£'000 £'000
Unrealised gains (losses) included above:
On investments 962 983
Total unrealised gains (losses) at 30 June 962 983
Reconciliation of movements in unrealised gains (losses)
Unrealised gains at 1 July 983 522
Less: in respect to disposals in the year - -
983 522
Add: net gains (losses) arising on revaluation arising
in the year		 (21) 461
Total unrealised gains (losses) at 30 June 962 983
2022
Unrestricted
funds		 Designated
funds		 Restricted
funds		 Total funds
Group £'000 £'000 £'000 £'000
Tangible fixed assets 49 - - 49
Intangible fixed assets 93 - - 93
Investments 4,259 - - 4,259
Current assets 45 771 143 959
Current liabilities (1,050) - - (1,050)
Total Funds 3,396 771 143 4,310
2022
Unrestricted
funds		 Designated
funds		 Restricted
funds		 Total funds
Charity £'000 £'000 £'000 £'000
Tangible fixed assets 49 - - 49
Intangible fixed assets 93 - - 93
Investments 4,259 - - 4,259
Current assets 25 771 116 912
Current liabilities (1,003) - - (1,003)
Total Funds 3,423 771 116 4,310

52

Notes to the financial statements

18 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

19 Related party transactions

The Kennedy Trust for Rheumatology Research (charity No. 260059) provided £5,000 sponsorship for the BSI awards. Professor Tracy Hussell is a trustee of this charity.

Matthias Eberl received a £250 BSI Congress 2021 Education and Public poster prize and a Communicating Immunology grant of £1,000.

There were no other related party transactions that required disclosure in the current financial period (2022: none).

53

Notes to the financial statements

20 Comparative consolidated statement of financial activities

Income from:
Donations
Investments
Charitable activities
Membership
Partnership work
Congress
Meetings and events
Journals		 General
Designated
Restricted
2022
£'000
£'000
£'000
£'000
6
-
274
280
151
-
-
151
160
-
-
160
91
-
45
136
512
-
-
512
59
-
-
59
913
-
-
913
Unrestricted funds
Total income
Raising funds
Investment Management Fees
Cost of raising funds
Charitable activities
Membership
Congress
Meetings and events
Publications and journals
Policy and Public Affairs
National Research support
Partnership work
Education and Careers
Diversity and inclusion
Public engagement
Communications
International work		 1,892
-
319
2,211
41
-
-
41
30
-
-
30
240
-
-
240
642
-
-
642
184
-
-
184
370
-
-
370
130
-
45
175
-
-
149
149
133
-
-
133
68
125
5
198
4
-
4
116
-
2
118
228
-
-
228
28
-
-
28
Total expenditure
2,214
125
201
2,540
Net income (expenditure) before gains (losses) on investments
and transfers
(322)
(125)
118
(329)
Net gains/(losses) on investments
(305)
-
-
(305)
Transfers between funds
90
(90)
-
-
Net income
(537)
(215)
118
(634)
Reconciliation of funds:
Funds brought forward
3,933
986
25
4,944
Funds carried forward
3,396
771
143
4,310

54

Notes to the financial statements

21 Charity statement of financial activities

Income from:
Grants and donations
Investments
Charitable activities
Membership
BSI-CIPN
Partnership work
Congress
Meetings and events
Journals
Training
Gift Aid and recharge from BSI
TradingLimited		 General
Designated
Restricted
Total
Total
funds
funds
funds
2023
2022
£'000
£'000
£'000
£'000
£'000
-
-
425
425
290
132
-
-
132
151
162
-
-
162
160
3
-
-
3
-
38
-
-
38
40
300
-
-
300
293
49
-
-
49
11
749
-
-
749
913
12
-
-
12
-

575
-
-
575
353
Unrestricted funds
Total income
Expenditure on:
Raising funds
Investment management fees
Cost of raising funds
Charitable activities
Membership
BSI-CIPN
Partnership work
Congress
Meetings and events
Journals
Training
Education and Careers
Diversity and inclusion
National Research support
Policy and Public Affairs
Public engagement
Communications
International work		 2,020
-
425
2,445
2,211
35
-
-
35
41
12
-
-
12
30
242
-
-
242
240
80
80
-
147
-
-
147
133
720
-
-
720
642
289
-
-
289
184
370
-
-
370
370
35
59
-
94
-
64
136
-
200
198
2
-
-
2
4
-
-
129
129
149
56
-
115
171
175
73
-
38
111
118
221
-
-
221
228
23
-
-
23
28
Total expenditure
Net income (expenditure)
before gains (losses) on
investments and transfers
Net gains/(losses) on
investments
Transfers between funds		 2,369
195
283
2,847
2,537
(349)
(195)
142
(402)
(326)
(7)
-
-
(7)
(305)
23
(23)
-
-
-
Net income/(deficit)
Reconciliation of funds:
Funds brought forward		 (333)
(218)
142
(409)
(632)
3,423
771
116
4,310
4,944
Funds carried forward 3,089
553
258
3,900
4,312

55

Board of Trustees

Position Trustee Date of appointment /
resignation
Previous
Past President Professor Arne Akbar Resigned December 2022
Past Chair of Forum Professor Ann Ager Resigned December 2022
EarlyCareer Trustee Dr Calum Bain Resigned July2022
Trustee Professor Matthias Eberl Resigned June 2023
Co-opted Trustee Dr Paul Harding Resigned June 2023
Trustee Professor Allan Mowat Resigned June 2023
Current
President Professor TracyHussell Appointed December 2022
Treasurer Dr Fiona Culley Re-appointed July2022
Chair of Forum Professor James Brewer Appointed December 2022
Clinical Secretary Professor Colin Dayan Appointed October 2019
EarlyCareer Trustee Dr Emma Chambers Appointed December 2018
Co-opted Trustee Robert Davies Re-appointed July2023
Trustee Professor Deborah Dunn-Walters Re-appointed July2023
Co-opted Trustee Dr Edith Hessel Appointed January2017
Trustee Professor Teresa Lambe Appointed December 2022
Co-opted Trustee James Lowe Appointed July2019
Co-opted Trustee David Pemberton Appointed July2023
EarlyCareer Trustee Dr Matthew Siggins Appointed July2022
Co-opted Trustee Dr Sinisa Savic Appointed July2022
Trustee Dr Divya Shah Re-appointed July2023
Trustee Dr Jessica Strid Appointed July2023

Board composition

Gender (%)

Length of tenure (%)

Female 53 Male 47

----- Start of picture text -----
< 1 year 40
1-3 years 27
> 4 years 33
----- End of picture text -----

56

Leadership

Board and Committee meetings and attendance

All Trustees are expected to attend each Board meeting and each Committee meeting for which they are members, unless there are exceptional citrcumstances preventing them from participating. The table below shows the attendance at Board and other BSI committees.

BSI-CIPN Membership
Steering Congress Finance Sub Representative Nominations
Trustees Board Group Committee Committee Forum Committee
Professor Tracy Hussell 4/4 - 3/3 - 3/3 1/1
Dr Fiona Culley 4/4 - 1/4 5/5 - -
Professor James Brewer 1/2 - - - 3/3 1/1
Professor Colin Dayan 4/4 - 1/4 - 1/4 -
Dr Emma Chambers 4/4 - - - - -
Robert Davies 4/4 - - - - 1/1
Professor Deborah Dunn-Walters 3/4 - - - - -
Dr Edith Hessel 3/4 - 1/1 - - 1/1
Professor Teresa Lambe 2/2 - - - - 1/1
James Lowe 3/4 - - 5/5 - -
David Pemberton 0/0 - - 0/0 - -
Dr Matthew Siggins 4/4 - - - - -
Dr Sinisa Savic 2/4 2/2 - - - -
Dr Divya Shah 2/2 - - - - -
Dr Jessica Strid 0/0 - - - - -

Senior Management Team

Name Position
Dr Doug Brown Chief Executive
Otto Balsiger Finance Director
Dr Jennie Evans Director of External Affairs
Jane Sessenwein Head of Events & Conferences
Lucy McIver Head of Publishing

57

Principal professional advisers

Name Advisor
Bankers Bank of Scotland
14/16 Cockspur Street
London
EC2V 6DL
External auditors Moore Kingston Smith LLP
9 Appold Street
London
EC2A 2AP
Investment advisers Abrdn (formerly Aberdeen Standard Chartered)
14th Floor
30 St Mary Axe
London
EC3A 8BF
Solicitors Russell Cooke LLP
2 Putney Hill
London
SW15 6AB

58

Committees

Nominations Committee

Members
Professor TracyHussell Chair,BSI President
Robert Davies BSI Co-opted Trustee
Professor James Brewer Trustee
Professor Teresa Lambe Trustee
Dr DougBrown BSI CEO(observer)

Finance Sub Committee

Members
Dr Fiona Culley BSI Treasurer
James Lowe Co-opted Trustee
David Pemberton Co-opted Trustee
Dr DougBrown BSI Chief Executive
Otto Balsiger BSI Finance Director

Forum

Members
Professor James Brewer Chair
Professor TracyHussell BSI President
Dr Colin Dayan Clinical Secretary
Dr Donald Palmer Education & Careers Secretary
Professor Matthias Eberl Public Engagement Secretary
Dr DougBrown BSI Chief Executive
Dr Jennie Evans BSI Director of External Affairs
Dr Patrick Cao Regional Representative - Scotland
Dr Julia Makinde Regional Representative - England
Dr Karim Dib Regional Representative - Northern Ireland
Dr Simone Cuff Regional Representative - Wales
Dr Louise Topping EarlyCareer Representative
Dr George Robinson EarlyCareer Representative
Dr George Robinson EarlyCareer Representative
Dr Edoardo Prediletto EarlyCareer Representative
Dr Lauren Campbell PhD Representative
Dr Jhanna Kryukova PhD Representative
Dr Chloe Pyle IndustryRepresentative
Dr Gareth-Rhys Jones Clinical Representative
Dr Tomaz Garcez Clinical Representative
Dr Rebecca McLean VeterinaryRepresentative

59

Committees

Congress Committee

Name Position
Professor Mark Coles BSI Congress Secretary
Professor TracyHussell BSI President
Dr Fiona Culley BSI Treasurer
Dr Colin Dayan BSI Clinical Secretary
Dr Edith Hessell Member
Dr Daniel O'Connor EarlyCareer Representative
Dr Graham Cook Member
Dr Helen McGettrick Member
Dr HenryMcSorley Member
Dr James Harker Member
Dr James Thaventhiran Clinical member
Dr Laura Rivino Member
Dr Margarita Dominguez Member
Dr Sandra Sacre Member
Jane Sessenwein BSI Head of Events & Conferences

BSI-CIPN Steering Group

Name Position
Dr Sinisa Savic Chair
Dr SuzyElcombe DeputyChair
Dr Catherine Stroud MembershipLead
Sarah Denman PharmacyRepresentative
Dr Lisa Devlin IndustryLiaison
Jull Edmonds NursingRepresentative
Dr KimberlyGilmour Clinical/Biomedical Scientist Representative
Professor Alex Ritcher Guidelines Lead
Dr Ravishnkar Sargur Member
Dr Patrick Yong Training& Education Lead
Dr Manisha Ahuja Postgraduate Doctor in TrainingRepresentative
Positiion vacant Patitent GroupLiaison
Dr James Thaventhiran Conference Lead(Co-opted member)
Dr Austen Worth Paediatric Representative and PID Registry Representative
(Ex-officio member)
Dr Claire Bethune CRG Representative(Ex-officio member)
Dr Sarah Goddard QPIDS Representative(Ex-officio member)
Dr DougBrown BSI Chief Executive

60

Journals

Clinicial and Experimental Immunology - Editorial Team

Name Position
Professor Leonie Taams Editor-in-Chief
Professor Angelo Manfredi Section Editor - autoimmunity
Professor Tanja de Gruiji Section Editor - cancer immunity
Professor Ciriaco Piccirillo Section Editor - immune-mediated inflammatorydiseases
Dr CindyMa Section Editor - immunodeficiency
Dr daniel Douek Section Editor - infectious diseases and vaccines
Professor Xiao-NingXu Section Editor - infectious diseases and vaccines
Professor Sandra Amor Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name Position
Professor Tim Elliot Editor-in-Chief
Professor Stefan Barth Regional Editor: Africa
Associate Professor Marianne Boes Regional Editor: Europe
Professor Adrianna Bonomo Regional Editor: South America
Professor Tao Dong Regional Editor: Asia
Dr Stephanie K Dougan Regional Editor: North America
Associate Professor Menno van Zelm Regional Editor: Australasia

Discovery Immunology - Editorial Team

Name Position
Professor Simon Milling Editor-in-Chief
Dr Philip Ahern Senior Editor
Dr Awen Gallimore Senior Editor
Dr Florent Ginhoux Senior Editor
Dr Emily Gwyer Findlay Senior Editor
Dr Lai Guan Ng Senior Editor
Professor Francisco J. Quintana Senior Editor
Dr Meera Ramanujam Senior Editor

61

Regional and Affinity groups

Affinity Groups

Group Position Member
Autoimmunity Affinity Group Chair
Professor Lucy Walker
Secretary
Dr Kathryn Steel
Treasurer
Dr James Pearson
Comparative Veterinary Immunology
Group		 Chair
Wilhelm Gerner
Secretary
Dr Lindert Benedictus
Treasurer
Dr Kate Sutton
Immunometabolism Affinity Group Co-Chair
Dr Laura Pallett
Co-Chair
Dr Linda Sinclair
Secretary
Dr Sarah Dimeloe
Treasurer
Dr Anna Schurich
Immunosenescence Affinity Group Chair
Dr Sian Henson
Secretary
Dr Natalie Riddell
Treasurer
Dr Catarina Henriques
Infection and Immunity Group
Inflammation Affinity Group Chair
Professor Peter Barlow
Treasurer
Dr Joanne Konkel
Communications
Dr Jack Rivers-Auty
Leukocyte Migration Group Chair
Dr Myriam Chimen
Secretary/Treasurer
Dr Graeme O'Boyle
Mathematical Modelling Group Chair
Dr Grant Lythe
Secretary
Professor Mark Coles
Treasurer
Dr Hashem Koohy
Neuroimmunology Group Chair
Dr Yvonne Dombrowski
Secretary
Dr Sarosh Irani
Teaching Affinity Group Co-chair
Professor John Currow
Co-chair
Dr Nigel Francis
Secretary
Dr Owen Kavanagh
Treasurer
Dr Becky Aicheler
Tumour Immunology Affinity Group Chair
Professor Benjamin Willcox
Secretary
Dr Seth B. Coffelt
Treasurer
Professor Awen Gallimore
Vaccine Affinity Group Chair
Dr Bernardo Villarreal-Ramos
Secretary
Dr Julia Tree
Treasurer
Dr Dirk Werling

62

Regional and Affinity groups

Regional Groups

Group Position Member
Aberdeen Immunology Group Chair
Dr Isabel Crane
Treasurer
Dr Janine Coombes
Bristol Immunology Group Chair
DrGareth Jones
Secretary
Dr Dronwen Burton
Treasurer
Dr Lindsay Nicholson
Cambridge Immunology
Group		 Chair
Dr Brian Ferguson
Secretary/Treasurer
Dr Louise Boyle
East Anglia Immunology
Group		 Secretary
Dr Anastasia Sobolewski
Treasurer
Dr Cristina Fanutti
Edinburgh Immunology Group Co-Chair
Dr Rebecca Gentek
Co-Chair
Dr Laura McCullock
Secretary
Dr Matthew Burgess
Secretary
Dr Tovah Shaw
Treasurer
Dr Sean Wattagedera
Greater Manchester
Immunology Group		 Chair
Dr Doug Dyer
Secretary
Dr Andrew Greenhaigh
Immunology North East Chair
Dr Kevin Marchbank
Secretary
Dr Antony Antoniou
Treasurer
Dr Andy Knight
London Immunology Group Chair
Dr Laura Pallett
Secretary
Dr Franze Progatzky
Treasurer
Dr George Finney
Midlands Immunology Group Chair
Dr Rebecca Drummond
Treasurer
Dr Martin Davey
Oxford Immunology Group Chair
Dr Roel De Maeyer
Secretary
Dr Elena Mitsi
South Wales Immunology
Group		 Chair
Dr You Zhou
Secretary
Dr Rebecca Aicheler
Treasurer
Dr Ceri Fielding

63

Regional and Affinity groups

Regional Groups

Group Position Member
Tayside Immunology Group Chair
Professor Simon Arthur
Secretary
Dr Mahima Swamy
Treasurer
Dr Shalini Pathak
Ulster Immunology Group President
Dr Yvonne Dombrowski
Secretary
Dr Karim Dib
Treasurer
Dr Rebecca Coll
Wessex Immunology Group Co-Chair
Professor Jessica Teeling
Co-Chair
Dr Sarah Buchan
Secretary
Dr Alison Hill
Treasurer
Dr Diogo Silva
West of Scotland Immunology
Group		 Chair
Dr Megan MacLeod
Secretary
Dr Ed Roberts
Treasurer
Dr Hannah Scales
Yorkshire Immunology Group Chair
Dr Gina Doody
Secretary
Dr Erica Wilson

64